دورية أكاديمية
Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes
| العنوان: | Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes |
|---|---|
| المؤلفون: | Redon, J, Pichler, G, Mule, G |
| المساهمون: | Redon, J, Pichler, G, Mule, G |
| بيانات النشر: | Lippincott Williams and Wilkins |
| سنة النشر: | 2016 |
| المجموعة: | IRIS Università degli Studi di Palermo |
| مصطلحات موضوعية: | Amlodipine, Antihypertensive agent, Blood pressure, Diabetes mellitu, Olmesartan, Perindopril, Adult, Aged, Angiotensin II Type 1 Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, Calcium Channel Blocker, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Combination, Female, Human, Hypertension, Imidazole, Male, Medication Adherence, Middle Aged, Tetrazole, Treatment Outcome, Internal Medicine, Physiology, Cardiology and Cardiovascular Medicine, Settore MED/09 - Medicina Interna, Settore MED/37 - Neuroradiologia |
| الوصف: | Introduction: Combination therapy is needed to control blood pressure (BP) in a large number of hypertensive patients with diabetes mellitus. Adherence to treatment is a major clinical problem; therefore, the time duration of the antihypertensive action of a drug determines BP control when a dose is skipped. Objectives: The aim was to determine whether the fixed-dose combination of olmesartan/amlodipine provides equal efficacy and safety as the perindopril/amlodipine combination when a drug dose is missed. Methods: In this noninferiority trial with a randomized, double-blind, double-dummy parallel group, controlled design, 260 patients received either olmesartan 20-40 mg/amlodipine 5-10 mg or perindopril 4-8 mg/amlodipine 5-10 mg for 24 weeks. The main outcome was the sitting office DBP after 24 weeks of treatment at 48 h from last administration. Results: The olmesartan/amlodipine combination reached noninferiority criteria in reduction of office DBP after 24 weeks of treatment and after the missed dose, compared with the perindopril/amlodipine combination (-11.7 and -10.5 mmHg, respectively). Office SBP and pulse pressure were significantly lower in both groups after 24 weeks of treatment and 48 h after the missed dose, observing a trend to greater SBP reduction in the olmesartan/amlodipine group. Conclusions: The combination olmesartan/amlodipine is safe, well tolerated, and as effective as the combination of perindopril/amlodipine in the control of essential hypertension in patients with diabetes mellitus. A missed dose does not leave the patients unprotected in both treatments; however, a faster control with less dose increment is observed with olmesartan/amlodipine. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/26867060; info:eu-repo/semantics/altIdentifier/wos/WOS:000369671400028; volume:34; issue:2; firstpage:359; lastpage:367; numberofpages:9; journal:JOURNAL OF HYPERTENSION; http://hdl.handle.net/10447/211213Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84957563456; http://journals.lww.com/jhypertensionTest |
| DOI: | 10.1097/HJH.0000000000000793 |
| الإتاحة: | https://doi.org/10.1097/HJH.0000000000000793Test http://hdl.handle.net/10447/211213Test http://journals.lww.com/jhypertensionTest |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.97DA9181 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1097/HJH.0000000000000793 |
|---|